Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

Mark These Tax-loss Selling Dates on Your Calendar (Updated 2024)

Investing in Graphene Companies (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Uranium Price Forecast: Top Trends That Will Affect Uranium in 2025

Trending Press Releases

Radiopharm achieves Nasdaq listing of ADS

First Helium Provides Year End Corporate Update

RAD 202 receives approval to start Phase 1 therapeutic trial

Mines and Money Miami Returns for Its Third Edition

Progress Update on Hydrogen Supply Chain and Prototype Tank Activities

Stardust Power Acquires Site, Receives Key Permit And Receives Approval For Major Construction To Commence

More Press Releases
Trending Companies

First Helium

HELI:CA

Black Swan Graphene

SWAN:CC

Metals Australia

MLS:AU

Soma Gold Corp.

SOMA:CA
More Companies
Trending Reports

2025 Gold Outlook Report

Silver Price Forecast - What Happened And Where Do We Go From Here?

2025 Uranium Outlook

2024 Oil & Gas Outlook Report

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Pardes Biosciences Inc.

NASDAQ:PRDS
Press Releases

Pardes Biosciences Inc is a clinical-stage biopharmaceutical company created for solving pandemic-sized problems, starting with COVID-19. It applies reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19.

Interactive Chart

×